Trials
2 active
2 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “To compare the safety of treatment with ELGN-2112 to placebo in preterm infants born less than 26 weeks GA and IUGR infants\<3rd percentile\* born at 26-32 weeks GA.”In the company’s words, NCT05904626 on ClinicalTrials.gov
- Tested for
- Intestinal Malabsorption (2 trials)
- Main trialPhase 3
- “The study will evaluate the effect of ELGN-2112 on intestinal malabsorption in preterm infants.”In the company’s words, NCT05670951 on ClinicalTrials.gov
Other drugs for Intestinal Malabsorption
- CrofelemerNapo Pharmaceuticals, Inc. · Phase 2/3
- TeduglutideTakeda · Phase 3
- PegtibatinaseTravere Therapeutics, Inc. · Phase 3
- ApraglutideVectivBio AG · Phase 3
- Larazotide AcetateInterlude Biopharma Co. · Phase 3
- GlepaglutideZealand Pharma · Phase 3
Coming up2
- Jun 2027Phase 2 trial completes · ClinicalTrials.gov
- Nov 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Nov 2027 | Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants | |
| Phase 2Recruiting | Jun 2027 | Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026